Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
GDTC
GDTC
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
GDTC News
STMicroelectronics Shares Rise 4.3% in Pre-Market Trading
Feb 09 2026
Benzinga
Align Technology Reports Strong Q4 Earnings Beat
Feb 05 2026
Benzinga
CytoMed Addresses False Claims, Reaffirms Research Progress
Jan 28 2026
Newsfilter
CytoMed Enters MOU with UMMC for First-in-Human Cancer Trial
Dec 08 2025
Globenewswire
CytoMed Partners with UMMC for First-in-Human Cancer Immunotherapy Trial
Dec 08 2025
Newsfilter
CytoMed Therapeutics Reveals Collaborative Study with The University of Texas, MD Anderson Cancer Center, Highlighting the Promise of Allogeneic γδ T Cells for Acute Myeloid Leukemia
Oct 02 2025
Newsfilter
CytoMed Therapeutics Expands into Autoimmune Diseases Following Recent Cord Blood Bank Acquisition
Aug 28 2025
Newsfilter
CytoMed Therapeutics Limited Unveils At-the-Market (ATM) Offering Initiative
Aug 19 2025
Newsfilter
CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates
Apr 28 2025
Newsfilter
CytoMed Therapeutics announces Chairman's Letter to the Company's shareholders
Feb 06 2025
Newsfilter
Why Inari Medical Shares Are Trading Higher By 21%; Here Are 20 Stocks Moving Premarket
Jan 07 2025
Benzinga
Singapore-Based CytoMed Therapeutics Stock Dips After SunAct Joins Clinical Trial As Joint Sponsor
Jan 06 2025
Benzinga
CytoMed Soars On Research Deal With SunAct Cancer Institute For Solid Tumor Treatment Trial In India
Jan 06 2025
NASDAQ.COM
CytoMed Therapeutics signs Business & Research Collaboration Agreement with India's SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India
Jan 06 2025
Newsfilter
Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies
Nov 20 2024
Newsfilter
CytoMed Therapeutics' first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
Oct 07 2024
Newsfilter
Show More News
